Oxford BioMedica plc (LON:OXB)’s share price reached a new 52-week high on Tuesday . The company traded as high as GBX 11.98 ($0.16) and last traded at GBX 10.62 ($0.14), with a volume of 20060000 shares. The stock had previously closed at GBX 11.10 ($0.15).

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 13 ($0.18) price target on shares of Oxford BioMedica in a report on Monday, January 8th.

In other Oxford BioMedica news, insider Lorenzo Tallarigo acquired 29,365 shares of the stock in a transaction dated Wednesday, December 20th. The stock was acquired at an average price of GBX 9 ($0.12) per share, with a total value of £2,642.85 ($3,584.01).

WARNING: “Oxford BioMedica (OXB) Reaches New 1-Year High at $11.98” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/23/oxford-biomedica-oxb-reaches-new-1-year-high-at-11-98.html.

About Oxford BioMedica

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.